Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Cordis' rapid-exchange heparin-coated stent:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Cordis' heparin-coated coronary stent for use on a rapid-exchange delivery system, called Raptorail. The Bx Velocity coronary stent with HEPACOAT was first approved for over-the-wire delivery in November 2000, when it became the first drug-coated stent to receive regulatory approval, says Cordis, a Johnson & Johnson firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel